A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases

[1]  Qiaobing Xu,et al.  Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles. , 2019, Biomaterials science.

[2]  Yang Zhang,et al.  3D organizational mapping of collagen fibers elucidates matrix remodeling in a hormone-sensitive 3D breast tissue model. , 2018, Biomaterials.

[3]  Khalid A. Hajj,et al.  Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA. , 2018, Nano letters.

[4]  C. Varga,et al.  Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center , 2017, Clinical lymphoma, myeloma & leukemia.

[5]  D. Dingli,et al.  Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. , 2017, Blood.

[6]  S. Devlin,et al.  Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis , 2016, Leukemia.

[7]  T. Spektor,et al.  Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients , 2016, Haematologica.

[8]  X. Ma,et al.  siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases , 2016, Gene Therapy.

[9]  P. Moreau,et al.  Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma , 2016, Haematologica.

[10]  Irene Georgakoudi,et al.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles , 2016, Proceedings of the National Academy of Sciences.

[11]  P. Hari,et al.  Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis , 2015, American journal of hematology.

[12]  Xiaoqun Gong,et al.  Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. , 2015, ACS nano.

[13]  K. Whitehead,et al.  Lipidoid Nanoparticles for siRNA Delivery to the Intestinal Epithelium: In Vitro Investigations in a Caco-2 Model , 2015, PloS one.

[14]  T. Olsson,et al.  γ-secretase directly sheds the survival receptor BCMA from plasma cells , 2015, Nature Communications.

[15]  I. Georgakoudi,et al.  Enhanced Intracellular siRNA Delivery using Bioreducible Lipid‐Like Nanoparticles , 2014, Advanced healthcare materials.

[16]  P. Hari,et al.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) , 2014, Haematologica.

[17]  L. Iyer,et al.  One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. , 2014, Blood.

[18]  N. Munshi,et al.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.

[19]  M. Raffeld,et al.  B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.

[20]  R. Falk,et al.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.

[21]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. Trinkaus-Randall,et al.  Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. , 2011, Blood.

[23]  D. Seldin,et al.  Preclinical Development of siRNA Therapeutics for AL Amyloidosis , 2011, Gene Therapy.

[24]  S. Kennel,et al.  Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. , 2010, Experimental hematology.

[25]  D. Reece,et al.  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.

[26]  M Boccadoro,et al.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders , 2009, Leukemia.

[27]  S. Jagannath.  Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. , 2007, Clinical lymphoma & myeloma.

[28]  C. Contag,et al.  Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. , 2005, Journal of biomedical optics.

[29]  J. Flaws,et al.  Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Bradwell.  Serum free light chain measurements move to center stage. , 2005, Clinical chemistry.

[31]  A. Little,et al.  Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia , 1999, British journal of haematology.

[32]  B. Klein,et al.  Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? , 1993, Blood.

[33]  R. Bataille,et al.  Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. , 1984, Blood.